Nasopharyngeal and oropharyngeal rinses with neutral electrolyzed water prevents COVID‑19 in front‑line health professionals: A randomized, open‑label, controlled trial in a general hospital in Mexico City

Gutiérrez‑García,Rafael; De La Cerda‑Angeles,Juan C.; Cabrera‑Licona,Ariana; Delgado‑Enciso,Ivan; Mervitch‑Sigal,Nicolas; Paz‑Michel,Brenda A.

doi:10.3892/br.2021.1494

Nasopharyngeal and oropharyngeal rinses with neutral electrolyzed water prevents COVID‑19 in front‑line health professionals: A randomized, open‑label, controlled trial in a general hospital in Mexico City

Authors:
- Rafael Gutiérrez‑García
- Juan C. De La Cerda‑Angeles
- Ariana Cabrera‑Licona
- Ivan Delgado‑Enciso
- Nicolas Mervitch‑Sigal
- Brenda A. Paz‑Michel
View Affiliations

Affiliations: Department of Otorhinolaryngology, Dr. Enrique Cabrera General Hospital, Mexico City 01620, Mexico, Department of Medical Direction, Dr. Enrique Cabrera General Hospital, Mexico City 01620, Mexico, Department of Research and Industrial Property, Esteripharma S.A. de C.V., Estado de México 50450, Mexico, Department of Molecular Medicine, School of Medicine, Universidad de Colima, Colima 28040, Mexico, Department of Medical Direction, Esteripharma México S.A. de C.V., México City 03100, Mexico
Published online on: December 15, 2021 https://doi.org/10.3892/br.2021.1494
Article Number: 11
Copyright: © Gutiérrez‑García et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The worldwide efforts that healthcare professionals are making in the COVID‑19 pandemic is well known, and the high risk of illness and death that front‑line staff experience on a daily basis is a reality, despite well‑defined protocols for the use of personal protective equipment. In addition, it is well known that vaccination is still faraway to be achieved worldwide and that new variants are emerging, thus additional protective measures must be explored. A prospective open‑label randomized controlled clinical trial was performed on front‑line medical staff from the Dr. Enrique Cabrera General Hospital in México City to evaluate the effectiveness of nasopharyngeal and oropharyngeal rinses with a neutral electrolyzed water, known as SES, to reduce the risk of COVID‑19 disease among front‑line, not vaccinated medical staff. A total of 170 volunteers were enrolled and equally divided in a control group and SES group. All members of the trial wore the adequate personal protection equipment at all times while performing their duties, as required by standard COVID‑19 safety protocols. Additionally, the SES group participants followed a prophylactic protocol with SES (oral and nasal rinses, three times a day for 4 weeks). All participants were monitored for COVID‑19 symptoms and disease in a time‑frame of 4 weeks and the incidence of illness per group was registered. The relative risk of disease, associated with each treatment was calculated. The presence of COVID‑19‑positive cases, in the group that received the nasal and oral rinses with SES was 1.2%, while in the group that did not do the SES rinses (control group), it was 12.7% (P=0.0039 and RR=0.09405; 95% CI of 0.01231‑0.7183). The prophylactic protocol was demonstrated as a protective factor, in more than 90%, for developing the disease, and without adverse effects. Nasal and oral rinses with SES may be an efficient alternative to reinforce the protective measures against COVID‑19 disease and should be further investigated. The present clinical trial was retrospectively registered in the Cuban public registry of clinical trials (RPCEC) database (March 16, 2021; PREVECOVID‑19: RPCEC00000357).

View Figures

View References

1	Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP and Cao JM: SARS-CoV-2: Structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 10(724)2020.PubMed/NCBI View Article : Google Scholar
2	Worldometer: COVID Live Update: 213,211,782 Cases and 4,452,192 Deaths from the Coronavirus, 2021.
3	Amnesty International: Mapping health worker deaths from COVID-19, 2020.
4	Jogalekar MP, Veerabathini A and Gangadaran P: SARS-CoV-2 variants: A double-edged sword? Exp Biol Med (Maywood). 246:1721–1726. 2021.PubMed/NCBI View Article : Google Scholar
5	Liu X, Liu Y, Wang L, Hu L, Liu D and Li J: Analysis of the prophylactic effect of thymosin drugs on COVID-19 for 435 medical staff: A hospital-based retrospective study. J Med Virol. 93:1573–1580. 2021.PubMed/NCBI View Article : Google Scholar
6	Dubina MV, Gomonova VV, Taraskina AE, Vasilyeva NV and Sayganov SA: Pathogenesis-based preexposure prophylaxis associated with a low risk of SARS-CoV-2 infection in healthcare workers at a designated COVID-19 hospital: A pilot study. BMC Infect Dis. 21(536)2021.PubMed/NCBI View Article : Google Scholar
7	Cegolon L, Javanbakht M and Mastrangelo G: Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents. Int J Hyg Environ Health. 230(113605)2020.PubMed/NCBI View Article : Google Scholar
8	O'Donnell VB, Thomas D, Stanton R, Maillard JY, Murphy RC, Jones SA, Humphreys I, Wakelam MJO, Fegan C, Wise MP, et al: Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function (Oxf). 1(zqaa002)2020.PubMed/NCBI View Article : Google Scholar
9	Carrouel F, Conte MP, Fisher J, Gonçalves LS, Dussart C, Llodra JC and Bourgeois D: COVID-19: A recommendation to examine the effect of mouthrinses with β-cyclodextrin combined with citrox in preventing infection and progression. J Clin Med. 9(1126)2020.PubMed/NCBI View Article : Google Scholar
10	Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM and Tessema B: Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone-iodine oral antiseptic rinse. J Prosthodont. 29:529–533. 2020.PubMed/NCBI View Article : Google Scholar
11	Caruso AA, Del Prete A and Lazzarino AI: Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic. Med Hypotheses. 144(109910)2020.PubMed/NCBI View Article : Google Scholar
12	Meyers C, Robison R, Milici J, Alam S, Quillen D, Goldenberg D and Kass R: Lowering the transmission and spread of human coronavirus. J Med Virol. 93:1605–1612. 2021.PubMed/NCBI View Article : Google Scholar
13	Seneviratne CJ, Balan P, Ko KKK, Udawatte NS, Lai D, Ng DHL, Venkatachalam I, Lim KS, Ling ML, Oon L, et al: Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized control trial in Singapore. Infection. 49:305–311. 2021.PubMed/NCBI View Article : Google Scholar
14	Huijghebaert S, Hoste L and Vanham G: Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19. Eur J Clin Pharmacol. 77:1275–1293. 2021.PubMed/NCBI View Article : Google Scholar
15	Yan P, Daliri EBM and Oh DH: New clinical applications of electrolyzed water: A review. Microorganisms. 9(136)2021.PubMed/NCBI View Article : Google Scholar
16	Takeda Y, Uchiumi H, Matsuda S and Ogawa H: Acidic electrolyzed water potently inactivates SARS-CoV-2 depending on the amount of free available chlorine contacting with the virus. Biochem Biophys Res Commun. 530:1–3. 2020.PubMed/NCBI View Article : Google Scholar
17	Moorman E, Montazeri N and Jaykus LA: Efficacy of neutral electrolyzed water for inactivation of human norovirus. Appl Environ Microbiol. 83:e00653–17. 2017.PubMed/NCBI View Article : Google Scholar
18	Tamaki S, Bui VN, Ngo LH, Ogawa H and Imai K: Virucidal effect of acidic electrolyzed water and neutral electrolyzed water on avian influenza viruses. Arch Virol. 159:405–412. 2014.PubMed/NCBI View Article : Google Scholar
19	Delgado-Enciso I, Paz-Garcia J, Barajas-Saucedo CE, Mokay-Ramírez KA, Meza-Robles C, Lopez-Flores R, Delgado-Machuca M, Murillo-Zamora E, Toscano-Velazquez JA, Delgado-Enciso J, et al: Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open-label, controlled trial. Exp Ther Med. 22(915)2021.PubMed/NCBI View Article : Google Scholar
20	Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, et al: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 25(2000045)2020.PubMed/NCBI View Article : Google Scholar
21	HyLown Consulting LLC: Power and Sample Size Calculators Compare 2 Proportions: 2-Sample, 1-Sided Calculator: 1. 2013.
22	Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D, Sampaziotis F, et al: SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 26:681–687. 2020.PubMed/NCBI View Article : Google Scholar
23	Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, et al: SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 382:1177–1179. 2020.PubMed/NCBI View Article : Google Scholar
24	To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, et al: Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect Dis. 20:565–574. 2020.PubMed/NCBI View Article : Google Scholar
25	Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T and Chen Q: High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 12(8)2020.PubMed/NCBI View Article : Google Scholar
26	Morita C, Sano K, Morimatsu S, Kiura H, Goto T, Kohno T, Hong WU, Miyoshi H, Iwasawa A, Nakamura Y, et al: Disinfection potential of electrolyzed solutions containing sodium chloride at low concentrations. J Virol Methods. 85:163–174. 2000.PubMed/NCBI View Article : Google Scholar
27	Giarratana N, Rajan B, Kamala K, Mendenhall M and Reiner G: A sprayable Acid-Oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS-Cov-2: A new potential solution for upper respiratory tract hygiene. Eur Arch Otorhinolaryngol. 278:3099–3103. 2021.PubMed/NCBI View Article : Google Scholar
28	Liu SY, Kang XL, Wang CH, Chu H, Jen HJ, Lai HJ, Shen SH, Liu D and Chou KR: Protection procedures and preventions against the spread of coronavirus disease 2019 in healthcare settings for nursing personnel: Lessons from Taiwan. Aust Crit Care. 34:182–190. 2021.PubMed/NCBI View Article : Google Scholar
29	Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, Rosser EC, Webb K and Deakin CT: Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 11(6317)2020.PubMed/NCBI View Article : Google Scholar
30	Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, Yee NTS, Liu C, Nerurkar SN, Kai JCY, et al: Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 93:1449–1458. 2021.PubMed/NCBI View Article : Google Scholar
31	Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KOA, Ahmed Z and Younas S: COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 13:1833–1839. 2020.PubMed/NCBI View Article : Google Scholar
32	Kimura KS, Freeman MH, Wessinger BC, Gupta V, Sheng Q, Ching Huang L, Von Wahlde K, Das SR, Chowdhury NI and Turner JN: Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus diesease 2019. Int Forum Allergy Rhinol. 10:1325–1328. 2020.PubMed/NCBI View Article : Google Scholar
33	World Health Organization (WHO): Coronavirus disease (COVID-19) advice for the public: Mythbusters. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters#saline. Accessed October, 2021.
34	Pan Y, Zhang D, Yang P, Poon LLM and Wang Q: Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 20:411–412. 2020.PubMed/NCBI View Article : Google Scholar
35	Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, et al: Virological assessment of hospitalized patients with COVID-2019. Nature. 581:465–469. 2020.PubMed/NCBI View Article : Google Scholar